Literature DB >> 30964200

WITHDRAWN: Interventions for guttate psoriasis.

Robert Chalmers1, Teresa O'Sullivan, Caroline M Owen, Christopher Em Griffiths.   

Abstract

BACKGROUND: Guttate psoriasis is a distinctive acute form of psoriasis which characteristically occurs in children and young adults. Very little specific evidence-based guidance is available in standard texts to help make rational decisions about treatment options.
OBJECTIVES: To assess the effectiveness of treatments for guttate psoriasis. SEARCH
METHODS: We searched the Cochrane Clinical Trials Register (Cochrane Library, Issue 3, 1999), Medline (1966- September 1999), Embase (1988-September 1999), Salford Database of Psoriasis Trials (to November 1999) and European Dermato-Epidemiology Network (EDEN) Psoriasis Trials Database (to November 1999) for terms GUTTATE and PSORIASIS. We also searched 100 unselected RCTs of psoriasis therapy and all 112 RCTs of phototherapy for psoriasis in the Salford Database of Psoriasis Trials for separate stratification for guttate psoriasis. SELECTION CRITERIA: Randomised trials in which patients with acute guttate psoriasis were randomised to different treatments, except those trials examining antistreptococcal interventions which are addressed in a separate Cochrane review. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial eligibility and quality. MAIN
RESULTS: No published report could be found to support or to challenge current commonly used methods of management.Only one trial which met the selection criteria was identified. In this small study of 21 hospitalised patients with guttate psoriasis, intravenous infusion of an n-3 fatty acid rich lipid emulsion was compared with placebo emulsion containing n-6 fatty acids. The n-3 preparation appeared to be of some benefit for patients with guttate psoriasis. AUTHORS'
CONCLUSIONS: There is currently no firm evidence on which to base treatment of acute guttate psoriasis. Studies comparing standard treatment modalities, including phototherapy and topical regimens, are required to enable informed decisions on treatment choices to be made.

Entities:  

Year:  2019        PMID: 30964200      PMCID: PMC6454586          DOI: 10.1002/14651858.CD001213.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  7 in total

1.  The role of streptococcal infection in the initiation of guttate psoriasis.

Authors:  N R Telfer; R J Chalmers; K Whale; G Colman
Journal:  Arch Dermatol       Date:  1992-01

2.  How great is the risk of further psoriasis following a single episode of acute guttate psoriasis?

Authors:  B A Martin; R J Chalmers; N R Telfer
Journal:  Arch Dermatol       Date:  1996-06

3.  Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial.

Authors:  J W Melski; L Tanenbaum; J A Parrish; T B Fitzpatrick; H L Bleich
Journal:  J Invest Dermatol       Date:  1977-06       Impact factor: 8.551

4.  A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients.

Authors:  C Green; T Lakshmipathi; B E Johnson; J Ferguson
Journal:  Br J Dermatol       Date:  1992-07       Impact factor: 9.302

5.  Double-blind, placebo-controlled study to evaluate the efficacy of fish oil and low-dose UVB in the treatment of psoriasis.

Authors:  A K Gupta; C N Ellis; D C Tellner; T F Anderson; J J Voorhees
Journal:  Br J Dermatol       Date:  1989-06       Impact factor: 9.302

6.  A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile.

Authors:  F Grimminger; P Mayser; C Papavassilis; M Thomas; E Schlotzer; K U Heuer; D Führer; K D Hinsch; D Walmrath; W B Schill
Journal:  Clin Investig       Date:  1993-08

7.  A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis.

Authors:  S B Bittiner; W F Tucker; I Cartwright; S S Bleehen
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.